206 related articles for article (PubMed ID: 17616807)
21. PAI-1 expression and its regulation by promoter 4G/5G polymorphism in clear cell renal cell carcinoma.
Choi JW; Lee JH; Park HS; Kim YS
J Clin Pathol; 2011 Oct; 64(10):893-7. PubMed ID: 21725041
[TBL] [Abstract][Full Text] [Related]
22. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
23. Urokinase-type plasminogen activator system and breast cancer (Review).
Han B; Nakamura M; Mori I; Nakamura Y; Kakudo K
Oncol Rep; 2005 Jul; 14(1):105-12. PubMed ID: 15944776
[TBL] [Abstract][Full Text] [Related]
24. Polymorphisms in predicted microRNA-binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker.
Brendle A; Lei H; Brandt A; Johansson R; Enquist K; Henriksson R; Hemminki K; Lenner P; Försti A
Carcinogenesis; 2008 Jul; 29(7):1394-9. PubMed ID: 18550570
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive survey of common genetic variation at the plasminogen activator inhibitor-1 locus and relations to circulating plasminogen activator inhibitor-1 levels.
Kathiresan S; Gabriel SB; Yang Q; Lochner AL; Larson MG; Levy D; Tofler GH; Hirschhorn JN; O'Donnell CJ
Circulation; 2005 Sep; 112(12):1728-35. PubMed ID: 16172282
[TBL] [Abstract][Full Text] [Related]
26. The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot AJ; van Tienoven DT; Beex LV; Sweep FC
Thromb Haemost; 2004 Mar; 91(3):514-21. PubMed ID: 14983227
[TBL] [Abstract][Full Text] [Related]
27. The -675 4G/5G polymorphism at the Plasminogen Activator Inhibitor 1 (PAI-1) gene modulates plasma Plasminogen Activator Inhibitor 1 concentrations in response to dietary fat consumption.
Pérez-Martínez P; Adarraga-Cansino MD; Fernández de la Puebla RA; Blanco-Molina A; Delgado-Lista J; Marín C; Ordovás JM; López-Miranda J; Pérez-Jiménez F
Br J Nutr; 2008 Apr; 99(4):699-702. PubMed ID: 17903340
[TBL] [Abstract][Full Text] [Related]
28. Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer.
Steiner E; Pollow K; Hasenclever D; Schormann W; Hermes M; Schmidt M; Puhl A; Brulport M; Bauer A; Petry IB; Koelbl H; Hengstler JG
Gynecol Oncol; 2008 Mar; 108(3):569-76. PubMed ID: 18222533
[TBL] [Abstract][Full Text] [Related]
29. Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients.
De Cremoux P; Grandin L; Diéras V; Savignoni A; Degeorges A; Salmon R; Bollet MA; Reyal F; Sigal-Zafrani B; Vincent-Salomon A; Sastre-Garau X; Magdelénat H; Mignot L; Fourquet A;
Anticancer Res; 2009 May; 29(5):1475-82. PubMed ID: 19443353
[TBL] [Abstract][Full Text] [Related]
30. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
Urban P; Vuaroqueaux V; Labuhn M; Delorenzi M; Wirapati P; Wight E; Senn HJ; Benz C; Eppenberger U; Eppenberger-Castori S
J Clin Oncol; 2006 Sep; 24(26):4245-53. PubMed ID: 16963728
[TBL] [Abstract][Full Text] [Related]
31. [The influence of I/D polymorphism of the angiotensin I converting enzyme (ACE) gene and 4G/5G polymorphism of plasminogen activator inhibitor (PAI-1) gene promoter on the haemostatic system in patients with essential hypertension and dyslipidemia].
Nowakowska A
Ann Acad Med Stetin; 2005; 51(1):95-105. PubMed ID: 16496609
[TBL] [Abstract][Full Text] [Related]
32. PAI-1 4G/5G insertion/deletion promoter polymorphism and microvascular complications in type 2 diabetes mellitus.
Funk M; Endler G; Exner M; Marculescu R; Endler L; Abrahamian H; Mauler H; Grimm A; Raith M; Mannhalter C; Prager R; Irsigler K; Wagner OF
Wien Klin Wochenschr; 2005 Oct; 117(19-20):707-10. PubMed ID: 16416371
[TBL] [Abstract][Full Text] [Related]
33. Gene polymorphisms of tissue plasminogen activator and plasminogen activator inhibitor-1 in Turkish patients with generalized aggressive periodontitis.
Emingil G; Berdeli A; Gürkan A; Han Saygan B; Köse T; Atilla G
J Clin Periodontol; 2007 Apr; 34(4):278-84. PubMed ID: 17257155
[TBL] [Abstract][Full Text] [Related]
34. Promoter polymorphisms in matrix metalloproteinases and their inhibitors: few associations with breast cancer susceptibility and progression.
Lei H; Hemminki K; Altieri A; Johansson R; Enquist K; Hallmans G; Lenner P; Försti A
Breast Cancer Res Treat; 2007 May; 103(1):61-9. PubMed ID: 17033924
[TBL] [Abstract][Full Text] [Related]
35. Influence of the 4G/5G PAI-1 genotype on angiotensin II-stimulated human endothelial cells and in patients with hypertension.
Roncal C; Orbe J; Rodriguez JA; Belzunce M; Beloqui O; Diez J; Páramo JA
Cardiovasc Res; 2004 Jul; 63(1):176-85. PubMed ID: 15194475
[TBL] [Abstract][Full Text] [Related]
36. Prognostic importance of PAI-1 in node negative breast cancer patients--results after 10 years of follow up.
Eljuga D; Razumovic JJ; Bulic K; Petrovecki M; Draca N; Bulic SO
Pathol Res Pract; 2011 May; 207(5):290-4. PubMed ID: 21459526
[TBL] [Abstract][Full Text] [Related]
37. PAI-1 Gene 4G/5G polymorphism and risk of type 2 diabetes in a population-based sample.
Meigs JB; Dupuis J; Liu C; O'Donnell CJ; Fox CS; Kathiresan S; Gabriel SB; Larson MG; Yang Q; Herbert AG; Wilson PW; Feng D; Tofler GH; Cupples LA
Obesity (Silver Spring); 2006 May; 14(5):753-8. PubMed ID: 16855181
[TBL] [Abstract][Full Text] [Related]
38. The prognostic value of BCAR1 in patients with primary breast cancer.
Dorssers LC; Grebenchtchikov N; Brinkman A; Look MP; van Broekhoven SP; de Jong D; Peters HA; Portengen H; Meijer-van Gelder ME; Klijn JG; van Tienoven DT; Geurts-Moespot A; Span PN; Foekens JA; Sweep FC
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6194-202. PubMed ID: 15448007
[TBL] [Abstract][Full Text] [Related]
39. Diabetic retinopathy, PAI-1 4G/5G and -844G/A polymorphisms, and changes in circulating PAI-1 levels in Tunisian type 2 diabetes patients.
Ezzidi I; Mtiraoui N; Chaieb M; Kacem M; Mahjoub T; Almawi WY
Diabetes Metab; 2009 Jun; 35(3):214-9. PubMed ID: 19419896
[TBL] [Abstract][Full Text] [Related]
40. [u-Plasminogen activator (urinary plasminogen activator, urokinase) (uPA) and its PA-1 type 1 inhibitor are not only prognostically but also predictively significant and support clinical decisions on therapy in primary carcinoma of the breast].
Harbeck N; Thomssen C
Zentralbl Gynakol; 2003 Sep; 125(9):362-7. PubMed ID: 14569518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]